Adjuvants are indispensable components of vaccines. Despite being widely used in
vaccines, their action mechanisms are not yet clear. With a greater understanding of the …

Recent progress has been made in both immunogen design and in achieving bnAb B cell
lineage induction in animal models and now in human clinical trials. With continued …

Antibody affinity maturation enables adaptive immune responses to a wide range of
pathogens. In some individuals broadly neutralizing antibodies develop to recognize rapidly …

Elicitation of antibodies that neutralize the tier-2 neutralization-resistant isolates that typify
HIV-1 transmission has been a long-sought goal. Success with prefusion-stabilized …

Low affinity is common for germline B cell receptors (BCR) seeding development of broadly
neutralizing antibodies (bnAbs) that engage hypervariable viruses, including HIV. Antibody …

A major goal of HIV-1 vaccine development is the induction of broadly neutralizing
antibodies (bnAbs). Although success has been achieved in initiating bnAb B cell lineages …

The CD4-binding site (CD4bs) is a conserved epitope on HIV-1 envelope (Env) that can be
targeted by protective broadly neutralizing antibodies (bnAbs). HIV-1 vaccines have not …

Effective vaccines elicit neutralizing antibodies and long-lasting memory, but this can be
challenging with some pathogens, such as HIV. A new study shows how a slow-delivery …

Guiding HIV-1 vaccine development with preclinical nonhuman... : Current Opinion in HIV and
AIDS Guiding HIV-1 vaccine development with preclinical nonhuman primate research : Current …

A protective HIV-1 vaccine has been hampered by a limited understanding of how B cells
acquire neutralizing activity. Our previous vaccines expressing two different HIV-1 …